• Deborah M Siegal, Geoffrey D Barnes, Nicole J Langlois, Adrienne Lee, Saskia Middeldorp, Leslie Skeith, William A Wood, and Grégoire Le Gal.
• Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
• Blood Adv. 2020 Dec 22; 4 (24): 6259-6273.

AbstractThrombosis has emerged as an important complication of coronavirus disease 2019 (COVID-19), particularly among individuals with severe illness. However, the precise incidence of thrombotic events remains uncertain due to differences in study design, patient populations, outcome ascertainment, event definitions, and reporting. In an effort to overcome some of these challenges and promote standardized data collection and reporting in clinical studies, the American Society of Hematology Research Collaborative COVID-19 Non-Malignant Hematology Task Force, in collaboration with the International Society on Thrombosis and Haemostasis COVID-19 Task Force, developed sets of data elements in the following domains: venous thromboembolism, myocardial infarction, stroke/transient ischemic attack, peripheral arterial thrombosis, bleeding, laboratory investigations, and antithrombotic therapy. Data elements in each of these domains were developed with 3 levels of detail to facilitate their incorporation into studies evaluating a range of interventions and outcomes. Previously published data elements were included where possible. The use of standardized variables in a range of clinical studies can enhance the quality of data collection, create efficiency, enhance comparison of results across studies, and facilitate future pooling of data sets.© 2020 by The American Society of Hematology.

22 keywords...

hide…